In the validation phase, we found that C1QA, MARCO, TXNDC15, IGFBP3, TNFRSF10C, TRIM5, LAYN, JAM3, RNF43, PPP1R14A, SPINT2, LGALS4, TOR1AIP1, AGER, CILP, CEACAM21, and IL10RB were significantly associated with PRAD risk. This evidence concerns the gene MARCO and prostate adenocarcinoma.